These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30904070)

  • 1. Data monitoring committees and randomized clinical trials.
    Trachtman H; Caplan AL
    Kidney Int; 2019 Apr; 95(4):992. PubMed ID: 30904070
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 3. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 4. Risks in Randomized Controlled Trials: Role of Interim Analysis and Data Monitoring Committee.
    Naqvi HA
    J Coll Physicians Surg Pak; 2015 Aug; 25(8):557-9. PubMed ID: 26305298
    [No Abstract]   [Full Text] [Related]  

  • 5. University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session).
    Dickersin K; Dixon D; Ferris F; Goldberg J; Kimmel S; Lachin J
    Clin Trials; 2018 Aug; 15(4):366-385. PubMed ID: 30021497
    [No Abstract]   [Full Text] [Related]  

  • 6. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 7. Data monitoring committees and stopping trials-Giving participants a voice.
    Trachtman H; Caplan A
    Contemp Clin Trials; 2018 May; 68():146. PubMed ID: 29567282
    [No Abstract]   [Full Text] [Related]  

  • 8. Data monitoring and safety committees and their operations.
    Rouse DJ
    Obstet Gynecol Surv; 2003 May; 58(5):329-36. PubMed ID: 12719675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

  • 10. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 11. Ethical Considerations for Unblinding a Participant's Assignment to Interpret a Resolved Adverse Event.
    Wilfond BS; Morales C; Johnson LM; Taylor HA
    Am J Bioeth; 2018 Oct; 18(10):66-67. PubMed ID: 30339065
    [No Abstract]   [Full Text] [Related]  

  • 12. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring clinical trials. Several points are contentious.
    Parry D
    BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinician-trialist rounds: 23. When an RCT's Data Center Report drowns vital information in seas of data: where's Waldo?
    Pogue J; Sackett DL
    Clin Trials; 2014 Oct; 11(5):601-4. PubMed ID: 24958742
    [No Abstract]   [Full Text] [Related]  

  • 15. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
    Bird SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
    [No Abstract]   [Full Text] [Related]  

  • 17. What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials?
    Clark WF; Sontrop JM
    Clin J Am Soc Nephrol; 2008 May; 3(3):895-8. PubMed ID: 18287258
    [No Abstract]   [Full Text] [Related]  

  • 18. Problems of stopping trials early.
    Guyatt GH; Briel M; Glasziou P; Bassler D; Montori VM
    BMJ; 2012 Jun; 344():e3863. PubMed ID: 22705814
    [No Abstract]   [Full Text] [Related]  

  • 19. The many moral responsibilities of independent data-monitoring committees.
    Braillon A
    Am J Bioeth; 2011 Mar; 11(3):16-7. PubMed ID: 21400378
    [No Abstract]   [Full Text] [Related]  

  • 20. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal.
    Dechartres A; Boutron I; Roy C; Ravaud P
    J Clin Epidemiol; 2009 Jul; 62(7):695-702. PubMed ID: 19135860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.